Results 151 to 160 of about 29,030 (239)

Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies

Therapeutic Advances in Neurological Disorders
Background: Aggressive disease control soon after multiple sclerosis (MS) diagnosis may prevent irreversible neurological damage, and therefore early initiation of a high-efficacy disease-modifying therapy (DMT) is of clinical relevance.
Helmut Butzkueven, Tomas Kalincik, Francesco Patti, Mark Slee, Bianca Weinstock-Guttman, Katherine Buzzard, Olga Skibina, Raed Alroughani, Alexandre Prat, Marc Girard, Dana Horakova, Eva Kubala Havrdova, Anneke Van der Walt, Sara Eichau, Robert Hyde, Nolan Campbell, Karthik Bodhinathan, Tim Spelman,   +18 more
doaj   +1 more source

Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US

ClinicoEconomics and Outcomes Research, 2013
Machaon M Bonafede,1 Barbara H Johnson,1 Crystal Watson2 1Truven Health Analytics, Cambridge, MA, USA; 2Biogen Idec, Weston, MA, USA Objectives: To evaluate multiple sclerosis (MS)-related health care-resource utilization and costs prior to and after ...
Bonafede MM, Johnson BH, Watson C
doaj  

Is it time to target no evident disease activity (NEDA) in multiple sclerosis? [PDF]

, 2015
Banwell, Bermel, Cohen, Cohen, Coles, Coles, Comi, Confavreux, Dobson, Erbayat Altay, Giovannoni, Giovannoni, Giovannoni, Hartung, Havrdova, Kappos, Leray, Levesque, Miller, Rio, Scalfari, Solomon, Sormani, Sormani, Tuohy, Zivadinov   +25 more
core   +1 more source

Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report

Journal of Medical Case Reports
Background Natalizumab is a monoclonal antibody used to treat patients with relapsing–remitting multiple sclerosis. Anemia is a recognized side effect, but it is usually mild and of a short duration when natalizumab is stopped.
Lars Henrik Dahl Hamnvik, Geir E. Tjønnfjord, Signe Spetalen, Jakob Dalgaard   +3 more
doaj   +1 more source

Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life

Patient Related Outcome Measures, 2014
Raquel Planas, Roland Martin, Mireia Sospedra Neuroimmunology and MS Research, Department of Neurology, University of Zurich, Zurich, Switzerland Abstract: Natalizumab was the first monoclonal antibody to be approved for the treatment of relapsing ...
Planas R, Martin R, Sospedra M
doaj  

Managing reactivation of multiple sclerosis during treatment with natalizumab. [PDF]

Mult Scler
Lizak N, Sharmin S, Horáková D, Havrdova EK, Eichau S, van der Walt A, Butzkueven H, Lechner-Scott J, Buzzard K, Skibina O, Gerlach O, Prat A, Girard M, Duquette P, Alroughani R, Patti F, Grand'Maison F, Sá MJ, Aguera-Morales E, Hodgkinson S, Grammond P, Kuhle J, Yamout B, Khoury SJ, Ozakbas S, Csepany T, John N, Laureys G, Terzi M, Amato MP, Boz C, Al-Asmi A, Cartechini E, Gouider R, Mrabet S, Roos I, Kalincik T.   +36 more
europepmc   +1 more source

Natalizumab and fumarate treatment differentially modulate CD4+ T cell and B cell subtypes in multiple sclerosis patients without impacting durable COVID-19 vaccine responses. [PDF]

Front Immunol
Curtin R, Velmurugu Y, Dibba F, Hao Y, Nyovanie S, Lopez A, Mieles D, Ng C, Perdomo K, Scott N, Lewin JB, Avila RL, Smrtka J, Patskovsky Y, Howard J, Silverman GJ, Krogsgaard M.   +16 more
europepmc   +1 more source

Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in Italy

ClinicoEconomics and Outcomes Research
Luca Prosperini,1 Lorenzo Pradelli,2 Laura Santoni,3 Daria Perini,3 Salvatore Cottone,4 Marco Vercellino5 1S. Camillo-Forlanini Hospital, Rome, Italy; 2AdRes Health Economics and Outcomes Resources, Turin, Italy; 3Biogen Italia, Milan, Italy; 4Department
Prosperini L, Pradelli L, Santoni L, Perini D, Cottone S, Vercellino M   +5 more
doaj  

Integrin β1 Demarks Precursors of Brain-Residing Antibody-Secreting Cells in Multiple Sclerosis. [PDF]

Neurol Neuroimmunol Neuroinflamm
Kuiper KL, Bogers L, Rip J, van Hasselt Y, Melief MJ, Wierenga-Wolf AF, Klein Kranenbarg RAM, Bindels E, van de Werken HJG, de Beukelaar J, Smets I, Wokke B, Smolders J, van Luijn MM.   +13 more
europepmc   +1 more source

Serum neurofilament light chain as a biomarker of disease control in multiple sclerosis: a real-world cross-sectional analysis of therapeutic regimens. [PDF]

J Neurol
Konitsioti AM, Schweitzer F, Johannis W, Steffen F, Bittner S, Fink GR, Schroeter M, Warnke C.   +7 more
europepmc   +1 more source